Understanding how certain immune cells affect heart transplant rejection
Dissecting the Role of Donor CCR2- Macrophages During Acute Cellular Rejection After Heart Transplantation
This study is looking at how certain immune cells called CCR2- macrophages affect heart transplant rejection, with the hope of finding better ways to help heart transplant patients do well without relying too much on strong medications that can have side effects.
Quick facts
| Grant type | Career grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Colorado Denver NIH-funded |
| Lab location | 1 site (Aurora, UNITED STATES) |
| Project ID | NIH-11077317 on NIH RePORTER |
What this research studies
This research investigates the role of specific immune cells, particularly CCR2- macrophages, in the process of heart transplant rejection. By examining how these cells interact with other immune populations, the study aims to uncover mechanisms that could improve transplant outcomes. The approach involves both laboratory experiments and analysis of immune responses in heart transplant patients. The goal is to develop new strategies that could enhance the success of heart transplants and reduce the need for harmful immunosuppressive therapies.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals who are undergoing or have undergone heart transplantation.
Not a fit: Patients who are not heart transplant recipients or those with contraindications for transplantation may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to improved heart transplant outcomes and reduced complications for patients.
How similar studies have performed: Previous research has shown promising results in understanding immune cell roles in transplant rejection, suggesting that this approach could yield valuable insights.
Where this research is happening
Aurora, UNITED STATES
- University of Colorado Denver — Aurora, United States (Active)
Researchers
- Principal investigator: Kopecky, Benjamin J — University of Colorado Denver
- Study coordinator: Kopecky, Benjamin J
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.